

Contents

Introduction to Safety Assessment in Drug and Medical	
Device Development	1
Global Pharmaceutical and Medical Device Markets	2
Legislative Considerations	6
Regulations: Human Pharmaceuticals.....	8
Special Cases: Biologics and Combination Products.....	10
Strategies for Development	10
Drugs	10
What You Need to Know to Start.....	12
Devices	13
References	15
Drugs: The General Case	17
IND/FIM Enabling	19
To Support Continued Clinical Development	19
To Support Marketing Approval	20
Subset: Special or Hazard Studies.....	20
ICH Requirements: The Global General Case	21
The First Rule	21
References	21
IND-Enabling Toxicology Programs	23
Toxicity Testing: Traditional Pharmaceuticals	26
Common Mistakes	27
Toxicity Testing of Pharmaceuticals: The General Approach	29
Developmental and Reproductive Toxicity Studies	30
Genetic Toxicity Assessment	31
Safety Pharmacology Studies.....	33
Toxicity Testing: Biotechnology Products	34

Toxicology Testing: Special Cases.....	37
Oral Contraceptives	37
Life-Threatening Diseases (Compassionate Use)	37
Antibiotics and Anti-Infectives	38
Special Cases.....	39
Direct to FIM Trials: Imaging Agents.....	39
Gene Therapy	40
Cellular (Stem Cell) Therapy	41
Excipients	41
Pediatric Claims and Juvenile Animal Studies.....	42
Exploratory INDs	43
References	44
 Nonclinical Safety Evaluation Studies Conducted to Support	
Continued Clinical Development.....	45
Repeat Dose Toxicity	45
Developmental and Reproductive Toxicology (DART).....	45
Impurities, Degradants, and Residual Solvents.....	47
Impurities	47
Residual Solvents	52
Extractables and Leachables	55
Residual Metals and Metal Catalysts	57
Safety Assessment of Metabolites (Metabolites in Safety	
Testing – MIST)	59
Local Tissue Tolerance.....	62
Nonclinical Abuse Liability	62
Drug Registration in Japan.....	62
Drugs in China; Pharmacology and Toxicology Study Information.....	63
References	63
 Supporting Marketing Applications.....	65
Non-Traditional (Other than NDA/505b (1)) Approval Routes	
and Requirements.....	65
Carcinogenicity	67
Pre- and Post-natal Development	67
Pediatric Population Studies.....	67
Special Cases.....	67
References.....	68
 Special Therapeutic Category and Route of Administration Cases.....	69
Specific Therapeutic Classes.....	69
Oncology Drugs	69
Activity Profile and Mechanism of Action.....	71
Mechanism(s) of Resistance.....	72
Special Considerations for Biopharmaceutical Studies.....	74

Nonclinical Data Evaluation to Support Clinical Trial Design	75
Start Dose for First Administration in Human	75
Dose Escalation and the Highest Dose in a Clinical Trial.....	75
Duration and Schedule of Toxicology Studies to Support	
Initial Clinical Trials.....	75
Duration of Toxicology Studies to Support Continued	
Development.....	76
Combinations of Pharmaceuticals	76
Studies in Pediatric Populations	76
Special Considerations for Biologics	77
Conjugated Agents	77
Liposomal Formulated Products	77
Evaluation of Drug Metabolites	79
Evaluation of Impurities	79
Other Life-Threatening Chronic Diseases	79
Imaging Agents	79
Antibiotics	81
Vaccines.....	81
Routes and Regimens Other than Oral and Daily	82
Combination Products	82
Historical Background	83
References	88
Device Safety Evaluation	91
Introduction	91
Regulatory Definition of Medical Devices.....	91
International Standards Organization.....	92
Topical Devices	97
Blood Path Direct	100
Japan.....	101
Other Regulatory Guidances	102
Biological Tests	102
References	108
Appendices	111
About the Author	113
Appendix A Notable Regulatory Internet Addresses	115
Index.....	123

Safety Evaluation of Pharmaceuticals and Medical
Devices

International Regulatory Guidelines

Gad, S.C.

2011, XI, 126 p., Hardcover

ISBN: 978-1-4419-7448-8